(NASDAQ: TCRX) Tscan Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.74%.
Tscan Therapeutics's earnings in 2026 is -$124,305,000.On average, 8 Wall Street analysts forecast TCRX's earnings for 2026 to be -$50,842,936, with the lowest TCRX earnings forecast at -$56,678,764, and the highest TCRX earnings forecast at -$46,386,010. On average, 8 Wall Street analysts forecast TCRX's earnings for 2027 to be -$57,861,613, with the lowest TCRX earnings forecast at -$73,009,933, and the highest TCRX earnings forecast at -$45,974,300.
In 2028, TCRX is forecast to generate -$53,829,468 in earnings, with the lowest earnings forecast at -$65,965,115 and the highest earnings forecast at -$43,229,565.